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INTRODUCTION
Therapeutics is a remarkably important domain of 
modern Medicine. It is rapidly advancing with the 
production of novel drugs and the amelioration of the 
older ones. Their use, though, is frequently limited be-
cause of the several side effects. Sometimes drugs that 
seem promising for the treatment of serious diseases 
in pre-clinical studies are abandoned when clinical tri-
als (in which a large number of subjects is exposed 
to the drug) prove that their use could cause several 
serious side effects1-2.
The main aim of Medicine and Pharmaceutics 
is the administration of the drug at the right mo-
ment, with a safe mode so that the desired effect is 
achieved3. The most prominent cause of drug failures 
(~ 40%) is associated with poor absorption, distribu-
tion, metabolism and excretion. Lack of significant 
efficacy, toxicity, and possible deleterious effects are 
other reasons to drop a drug2. Nanotechnology offers 
significant advantages in drug administration. Espe-
cially dendrimers could have wide clinical use as drug 
carriers. Possibly, their unique properties allow them 
to counter the causes of drug failure.
DENDRIMERS: UNIQUE PROPERTIES-
PROMISING CARRIERS
The word dendrimer comes from the Greek word 
“dendron” which means “tree”, thus indicating its 
tree-shaped structure. They are highly branched, with 
many arms held on a central core, symmetric and 
three-dimensional3-5. Synthesis includes two major 
strategies: in the first one (divergent method) which 
was introduced by Tomalia and colleagues, synthesis 
begins from the core. Then synthetic or natural sub-
strates are added according to several rules. In the sec-
ond strategy (convergent method) Hawker and Frechet 
began the synthesis from what will become the sur-
face of the dendrimer and proceeded to the core6. Both 
methods include a multi-step polymerisation process. 
In each step, a layer of monomeric molecules is added 
and the number of layers defines the generation of the 
dendrimer5. Their size is of nanoscale diameter (10-9 
m) because of their controlled synthesis strategy7.
Dendrimers can be made from a wide variety of 
biocompatible materials, the most frequently used 
are polyamidoamine (PAMAM), polyethylene oxide 
(PEO), polypropylene imine (PPI), polyethyleneimine 
(PEI), polyethylene glycol (PEG) etc3. Additionaly 
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dendrimers may be produced exclusively from amino 
acids. For example, lysine can be used as a trivalent 
core and a branching unit too8. 
Dendrimers are potential nanocarriers of agents 
because they are highly biocompatible and water sol-
uble4. Their solubility is related to the surface func-
tional groups, their generation and even the core syn-
thesis7. Consequently, drugs that appear to have poor 
pharmacokinetic parameters, such as the hydrophobic 
ones, may be efficiently administered with these nano-
molecules. Furthermore dendrimers show low toxic-
ity and organ accumulation9-10 possibly due to the fact 
that drug release is achieved only near its target (e.g. 
a tumor)11. Another potential advantage that could be 
obtained by the use of this type of nanocarriers is  the 
extended plasma half-life of the drug12-13. Compared 
to linear polymers, dendrimers are more slowly ex-
creted with the urine probably because of their de-
creased ability to filtrate through the renal glomerule4 
whereas urinary clearance decreases with molecular 
weight13. Beyond anatomical obstacles, they may also 
cross cellular barriers via transcellular or paracellular 
pathways by-passing some efflux transporters, such 
as P-glycoprotein (Pgp) or some drug metabolism 
enzymes like hepatic Cytochrome 450 (CYP450)14-15. 
An endocytosis-mediated transport has been reported 
too16. It should be noted that efforts are being made 
so that the intracellular delivery of dendrimers can 
be controlled. Huang and colleagues, created two 
Newkome-type dendrimers, differentiated over a var-
ied alkyl spacer with guanidine end moieties. One of 
them could be delivered mainly in the cytosole and the 
other in the nucleus17.
Two major approaches have been developed for 
the transport of these molecules to the desired site 
in the body. The first one includes encapsulation of 
the drug into the cavities of the dendrimer. The en-
capsulated molecule is non-covalently attached via 
ionic, hydrogen bonds, Van der Waals or hydrophobic 
interactions2,7,18. Thus the drug is safely carried be-
cause interactions with molecules of its environment, 
that could eliminate it or affect its pharmacokinetic 
parameters, are avoided19. It has been observed (at 
PAMAM dendrimers) that pH modulates drug solubil-
ity and release by affecting the ionisation condition of 
the molecule. For example acidic drugs are protonated 
at relatively low pH and the opposite occurs when ba-
sic drugs are exposed to the same conditions. In addi-
tion, low pH promotes the protonation of the tertiary 
amines in the cavities of dendrimer, thus weakening 
the drug-dendrimer interactions. As a result  drug 
release is favored19-20. However, it has been reported 
that protonation of the administered molecule may en-
hance its hydrophobic interactions with the dendrimer 
cavities, as Gupta and colleagues demonstrated with 
studies on PPI dendrimers and hydrophobic drugs. 
Thus it could be assumed that both pH and the func-
tional groups of the drug play a role in solubility en-
hancement18. The second approach for drug delivery 
includes covalent conjugation of the drug to the den-
drimer periphery. It permits a more efficient control 
of drug release and cell targeting as the administered 
molecule diffuses more slowly and allows interaction 
with specific interfaces4,7,19. In some cases conjugation 
of increased amounts of several agents is precluded 
because of the steric hindrance. For example in the 
case of quinolone this obstacle was overcome with the 
use of a glycine molecule. Glycine was firstly attached 
to the agent and then conjugated to the surface of a 
PEGylated carrier21. On the contrary, high amounts of 
peripherally and covalently bound hydrophobic mol-
ecules may cause dendrimer aggregation5. 
 Low polydispersity (e.g. the low distribution of 
molecular weights) of dendrimers allows reproducible 
pharmacokinetic pattern, whereas their multivalency 
permits the precise attachment of several molecules 
to their periphery. These molecules may serve as solu-
bilising or targeting groups for a more efficient and 
precise distribution in the blood that will lack many 
of the adverse effects4. Furthermore, they may reduce 
toxicity caused by specific end groups at the periphery 
of the dendrimer. PEG is an exceptionally important 
modifying molecule18. Like other hydrophilic mol-
ecules, PEG reduces immunogenicity and uptake by 
the organs of the reticulo-endothelial system (RES)2. 
Furthermore, PEGylation increases biocompatibility 
of dendrimers and offers greater protection of the de-
livered drug, as it was observed in experiments with 
PAMAM dendrimers22.
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IMPLICATION IN AN IDEAL  
DRUG DELIVERY SYSTEM
“Snake in the grass” for cancer
The use of dendrimers in drug administration may 
offer significant advantages in the treatment of seri-
ous diseases. They have been considered for the ad-
ministration of several drugs, most of which are used 
for the treatment of cancer. Two major charasteristics 
of malignant tumors render them potential targets of 
dendrimer-mediated pharmacotherapy. First of all, tu-
mor vasculature has increased permeability to macro-
molecules as well as decreased lymphatic drainage. 
This is called “enhanced permeation and retention” 
effect (EPR). Because of EPR, dendrimer-conjugated 
drugs may appear in relatively high concentration in 
these tissues3,13.
High concentration of dendrimer-conjugated an-
tineoplasmatic drugs may also be achieved through 
active targeting of cancer cells or their vasculature. 
Previous efforts including antibody-conjugated drugs 
that could recognise special antigens on cancer cells 
resulted in very low efficacy23. On the other hand nan-
otechnology, at least for the moment, has more prom-
ising perspectives in this area of research. Ligands on 
the periphery of the dendrimers act as “detectors” of 
special molecules expressed only (or at least in greater 
proportions) in the membrane of the target4,7. Some of 
these molecules are the folate receptor that mediates 
the endocytosis of folic acid, the transferrin receptor 
for the endocytosis of Fe3+, the epidermal growth fac-
tor receptor and the lectin receptor24. Folic acid is a 
significant representative of this category of ligands. 
Myc and colleagues conjugated folic acid molecules 
to PAMAM dendrimers carrying the apoptosis-induc-
ing agent stavrosporine. Interestingly an active inter-
nalisation of the nanocomplex in KB cells (human 
epidermoid carcinoma cells) that carry a great amount 
of membrane folate receptors was observed. On the 
contrary in another human cancer cell line (UMSCC-
38) which did not carry these receptors, no internali-
sation of the drugs appeared. Probably the dendritic 
molecule contributed to this preventive role25. Anti-
bodies may also act as active targeting molecules for 
cancer cells like J591 antibody (special for prostate 
specific membrane antigen)26. Nevertheless attaching 
multiple molecules to a single dendrimer contributes 
several deficits to the therapy, such as low water solu-
bility or biological activity. To overcome this obstacle, 
the different molecules may be attached to two differ-
ent dendrimers, assembled with an oligonucleotide27.
In the last few years great progress has been 
achieved in the linkage between nanotechnology ap-
plications and cancer therapeutics. Chemotherapeutic 
drugs are usually associated with not only important 
adverse effects but also low efficacy (drug resistance). 
Dendrimers are useful tools for the circumvention 
of these “barriers”. Methotrexate was less toxic and 
more efficient when administered through a PAMAM-
dendrimer than as a free drug2. Doxorubicin, in addi-
tion, administered with polyester bow-tie biodegrad-
able dendrimers, had extended plasma half-life. This 
favored the EPR effect to the C-26 colon carcinoma 
cell line, especially when the tumor vasculature had 
grown enough13. The use of PAMAM dendrimers as 
oral carriers of doxorubicin has encouraging results 
mainly because they may by-pass both the Pgp efflux 
transporter and CYP450 metabolism. Thus absorption 
of the drug from the intestinal epithelium as well as its 
bioavailability and other pharmacokinetic parameters 
are greatly increased14. Kono and his colleagues found 
that toxicity of doxorubicin was elevated, when cova-
lently conjugated to PEGylated PAMAM dendrimers 
through a glutamic acid residue, even against doxoru-
bicin-resistant cells28.
Analogues of camptothecin 10-hydroxycamp-
tothecin), 7-butyl-10-aminocamptothecin, were en-
capsulated in biodegradable dendrimers made of 
glycerol and succinic acid. An increase of cellular 
uptake and drug retention in human breast adenocar-
cinoma cells (MCF-7) was reported29. Recent studies 
indicate that G5 PAMAM dendrimers are used for the 
delivery of BH3 peptide (an apoptotic agent, homolo-
gous to the anti-apoptotic Bcl-2 protein) to KB cancer 
cells. Folic acid conjugated to the carriers provided 
the ability of active targeting of these cells30. In ad-
dition PEGylated G6 lysine dendrimers (KG6) were 
examined for their potency as antineoplasmatic drug 
carriers. It seems that PEGylation prevented the early 
elimination of the carrier by reducing its hepatic and 
renal accumulation whereas its tumor concentration 
was enhanced because of the EPR effect. Interest-
ingly these PEGylated dendrimers conserved their 
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blood concentration profile after a second administra-
tion. On the contrary PEGylated liposomes appeared 
the accelerated blood clearance (ABC) effect when a 
second dose was administered mainly because of an 
increased uptake by the RES31. There are several other 
antitumor drugs that have been studied in experiments 
with dendrimers. Some of them are colhicin32, pacli-
taxel33 and flouorouracil34.
On the other hand dendrimers have been tested in 
several other therapeutic strategies against neoplasms. 
One of them is photodynamic therapy which consists 
in the delivery of light-activated photosensiting drug 
in tumor tissue. When activated, the drug induces oxi-
dative stress and subsequently cell death. In addition 
dendrimers could be used in boron neutron capture 
therapy. They may carry 10B to tumor tissue where, 
after irradiation with low energy or thermal neutrons, 
toxic products kill malignant cells4. Taken together, 
the majority of these reports suggests that nanotech-
nology and particularly dendrimers may be promising 
weapons for the battle against cancer.
Facing other diseases 
Recent research has revealed the efficacy of the use 
of dendrimers for the administration of several other 
therapeutical agents. One of the first applications of 
dendrimers was against infectious diseases. Dendrim-
ers may offer advantages to the antimicrobial pharma-
cotherapy. It is well known that PAMAM dendrimers 
with primary amine surface functional groups may en-
ter the cellular mebrane. Sulfomethoxazole (a sulfon-
amide derivative poorly soluble and thus presenting 
low bioavailability) was administered with PAMAM 
dendrimers in vitro. Elevated antimicrobial activ-
ity against E. Coli was demonstrated apart from an 
increase in water solubility in these cases35. Besides, 
PAMAM-conjugated sunfadiazine was also controlled 
for its anti-toxoplasmic properties and results were 
more than encouraging36. Dendrimeric peptides them-
selves may act as antimicrobial agents. Structurally 
they contain several motifs, like BHHB (where “B” 
is a basic and “H” a hydrophobic amino acid) in their 
sequence. These motifs are also found in natural an-
timicrobial petides like tachyplesins and protegrins37. 
Moreover studies with PAMAM dendrimers carrying 
quinolone demonstrated similar results38. 
Several experiments with the use of nonsteroidal 
antiinflammatory drugs (NSAIDs) have -as well- in-
teresting findings which propose a major role of den-
drimers in anti-inflammatory therapy39. Cheng and 
colleagues suggested the transdermal delivery of 
dendrimer-NSAIDs complexes40. Interestingly active 
targeting of inflammatory tissue in rats with rheuma-
toid arthritis may also be achieved. Researchers used 
folic acid in order to lead dendrimers loaded with in-
domethacin to the desired site (joints). The expression 
of FRγ subtype of folate receptor in activated synovial 
macrophages offers this potential strategy of active 
targeting41.
CONCLUSION
Dendrimers constitute a significant and quite prom-
ising route of drug administration. Great enthusiasm 
about them is shown by a major part of the scientific 
community. This novel way of drug administration re-
quires the collaboration of experts of many fields and 
has high costs (complex biomaterials). Although ex-
perimental results are more than encouraging, further 
evaluation of dendrimers through laboratory and clin-
ical trials will clarify if these nano-carriers are safe for 
massive use3. It seems that “a new day has come” in 
modern therapeutics of serious disorders.
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